Evidence map›Paper›PMID 38934080›Full record

ArticleHaematologica2024

Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.

Marta Elżbieta Kasprzyk, Weronika Sura, Marta Podralska, Marta Kazimierska, Annika Seitz, Wojciech Łosiewski, Tomasz Woźniak, Jeroen E J Guikema, Arjan Diepstra, Joost Kluiver and 3 more

Abstract read
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marta Elżbieta KasprzykInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Weronika SuraInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Marta PodralskaInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Marta KazimierskaInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Annika SeitzDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen.
Wojciech ŁosiewskiInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Tomasz WoźniakInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Jeroen E J GuikemaDepartment of Pathology, Amsterdam University Medical Center, Amsterdam.
Arjan DiepstraDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen.
Joost KluiverDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen.
Anke Van den BergDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen.
Natalia RozwadowskaInstitute of Human Genetics, Polish Academy of Sciences, Poznań.
Agnieszka Dzikiewicz-KrawczykInstitute of Human Genetics, Polish Academy of Sciences, Poznań. agnieszka.dzikiewiczkrawczyk@igcz.poznan.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise mechanisms of their involvement in control of the translocated oncogenes is limited. The goal of this project was to define the critical regions in the IGH regulatory elements and identify enhancer RNA (eRNA). We designed a single guide RNA library densely covering the IGH enhancers and performed tiling CRISPR interference screens in three NHL cell lines. This revealed three regions crucial for NHL cell growth. With chromatin- enriched RNA sequencing we showed transcription from the core enhancer regions and subsequently validated expression of the eRNA in a panel of NHL cell lines and tissue samples. Inhibition of the essential IGH enhancer regions decreased expression of eRNA and translocated oncogenes in several NHL cell lines. The observed expression and growth patterns were consistent with the breakpoints in the IGH locus. Moreover, targeting the Eμ enhancer resulted in loss of B-cell receptor expression. In a Burkitt lymphoma cell line, MYC overexpression partially rescued the phenotype induced by IGH enhancer inhibition. Our results indicated the most critical regions in the IGH enhancers and provided new insights into the current understanding of the role of IGH enhancers in B-cell NHL. As such, this study forms a basis for development of potential therapeutic approaches.

Indexed as

Enhancer Elements, GeneticImmunoglobulin Heavy ChainsLymphoma, Non-HodgkinCell Line, TumorCell SurvivalCRISPR-Cas SystemsGene Expression Regulation, NeoplasticHumansTranslocation, GeneticImmunoglobulin Heavy Chains

Identifiers

PMID38934080
PMCPMC11609794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.